Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blind spot

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    67 result(s) found for: Blind spot. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2020-003184-25 Sponsor Protocol Number: 20190232 Start Date*: 2021-02-12
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 3, Multicenter , Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) EE (Completed) BG (Prematurely Ended) HU (Completed) SK (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-000542-18 Sponsor Protocol Number: 20200497 Start Date*: 2021-12-21
    Sponsor Name:Amgen Inc.
    Full Title: A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With ...
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2019-003851-12 Sponsor Protocol Number: 20968 Start Date*: 2020-06-25
    Sponsor Name:Bayer AG
    Full Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
    Medical condition: Neovascular Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) LV (Completed) PT (Completed) EE (Completed) AT (Completed) FR (Completed) SK (Completed) BG (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000331-16 Sponsor Protocol Number: C-935788-050 Start Date*: 2014-07-28
    Sponsor Name:Rigel Pharmaceuticals Inc
    Full Title: A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy
    Medical condition: IgA nephropathy (IgAN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003901-10 Sponsor Protocol Number: 250317BS Start Date*: 2006-12-06
    Sponsor Name:Neosil Inc.
    Full Title: A randomized, placebo controlled, double-blind study to evaluate the efficacy of topical formulations in male subjects with androgenetic alopecia
    Medical condition: The study will be performed in male subjects with Norwood/Hamilton grades III - IV, androgenetic alopecia.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002546-36 Sponsor Protocol Number: 2018-002546-36 Start Date*: 2020-03-10
    Sponsor Name:Oslo University Hospital
    Full Title: TENECTEPLASE IN CENTRAL RETINAL ARTERY OCCLUSION STUDY (TenCRAOS): A PROSPECTIVE, RANDOMIZED-CONTROLLED, DOUBLE-DUMMY, DOUBLE-BLIND PHASE 3 MULTI-CENTRE TRIAL OF TNK 0.25 MG/KG + PLACEBO VS. ASA...
    Medical condition: Central retinal artery occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) LT (Completed) FI (Trial now transitioned) DK (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-013795-44 Sponsor Protocol Number: NCHECR-ENCORE1 Start Date*: 2012-06-21
    Sponsor Name:The Kirby Institute (formerly National Centre in HIV Epidemiology and Clinical Research (NCHECR)), University of New Sou
    Full Title: A randomised, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase in...
    Medical condition: Human Immunodeficiency Virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10070257 Human immunodeficiency virus test positive LLT
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004648-54 Sponsor Protocol Number: ASF-1057-302 Start Date*: 2007-12-10
    Sponsor Name:Astion Pharma A/S
    Full Title: Efficacy and safety of ASF-1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, multi-centre, double-blind, active comparator (ketoconazole cream 2%) and placebo cont...
    Medical condition: Seborrhoeic dermatitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000706-34 Sponsor Protocol Number: A3921237 Start Date*: 2014-10-06
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO ASSESS THE IMMUNE RESPONSE FOLLOWING ADMINISTRATION OF ZOSTER VACCINE TO SUBJECTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB (C...
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000895-16 Sponsor Protocol Number: SPP100C2201 Start Date*: 2005-04-01
    Sponsor Name:Novartis Ireland Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of aliskiren on proteinuria when added to standardized losartan therapy and optimal antihyp...
    Medical condition: patients with hypertension, Type 2 DM and proteinuria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) SK (Prematurely Ended) DK (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003126-23 Sponsor Protocol Number: D6402C00001 Start Date*: 2021-02-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Fail...
    Medical condition: Heart Failure and Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) LT (Completed) HU (Completed) DK (Completed) SE (Completed) CZ (Completed) SK (Completed) BG (Completed) PL (Completed) DE (Completed) IT (Completed) ES (Restarted)
    Trial results: View results
    EudraCT Number: 2011-002001-30 Sponsor Protocol Number: IMUP Start Date*: 2011-12-09
    Sponsor Name:INFECTOPHARM Arzneimittel und Consilium GmbH
    Full Title: Multicenter, prospective, double-blind, two-armed phase III study for efficacy and safety of the topic impetigo therapy of two 2 % mupirocin ointments
    Medical condition: Impetigo
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002716-27 Sponsor Protocol Number: ALN-CC5-005 Start Date*: 2019-06-11
    Sponsor Name:Alnylam Pharmaceuticals Inc
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients with IgA Nephropathy
    Medical condition: Immunoglobulin A nephropathy (IgAN)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004110-32 Sponsor Protocol Number: D1521C00002 Start Date*: 2005-12-01
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients wit...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002959-34 Sponsor Protocol Number: RETRAP Start Date*: 2013-03-11
    Sponsor Name:Sønderjylland Hospital, department of neurology
    Full Title: RETRAP - A double blind, randomized, placebo controlled study of the effect of the combination of resistance training and prolonged release fampridine on muscle strength in the lower extremities, w...
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004852 10052785 Multiple sclerosis acute and progressive HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004627-38 Sponsor Protocol Number: ASF-1057-301 Start Date*: 2007-11-12
    Sponsor Name:Astion Pharma A/S
    Full Title: Efficacy and safety of ASF 1057 cream 0.5% in the treatment of seborrhoeic dermatitis: A phase III randomised, double-blind, vehicle- and placebo controlled, parallel groups, multi-centre trial
    Medical condition: Seborrhoeic dermatitis.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) DK (Completed) FR (Completed) FI (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003453-34 Sponsor Protocol Number: 201755 Start Date*: 2015-06-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheuma...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004815-33 Sponsor Protocol Number: TransCon_PTH_TCP-201 Start Date*: 2019-09-27
    Sponsor Name:Ascendis Pharma Bone Diseases A/S
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial with an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administ...
    Medical condition: Hypoparathyroidism (HP) in Adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2021-003604-40 Sponsor Protocol Number: AFT-RAP-01 Start Date*: 2023-03-21
    Sponsor Name:AFT Pharmaceuticals Ltd.
    Full Title: Rapamycin Dose-Ranging Efficacy Study: A Phase II, proof of concept, double-blind, placebo-controlled, randomized, parallel-group, dose-response comparison of the effects of different strengths of ...
    Medical condition: Subjects diagnosed with port wine stains
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10036197 Port wine stain LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013157-15 Sponsor Protocol Number: 1218.74 Start Date*: 2010-10-14
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca...
    Medical condition: Patients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV events prior to informed consent can be enrolled in the study.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000072461 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) IE (Completed) FI (Completed) SE (Completed) GB (Completed) SK (Completed) IT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 00:54:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA